Efficacy of Disease-Modifying Treatments in Transthyretin Amyloid Cardiomyopathy: A Systematic Review and Meta-Analysis of Five Phase III Randomized Controlled Trials
Hung, Y.-H.; Tsai, C.-H.; Kao, T.-W.; Wu, Y.-W.; Yu, W.-C.; Carigi, S.; Sperry, B. W.; Perlini, S.; Lin, Y.-H.
Show abstract
Background Several disease-modifying agents for transthyretin amyloid cardiomyopathy (ATTR-CM) have been investigated, but differences in trial design and background stabilizer use complicate interpretation of their efficacy. This meta-analysis assessed their efficacy overall and by background stabilizer use. Methods PubMed, Embase, and the Cochrane Library were searched through September 2026 for phase III randomized, placebo-controlled trials of disease-modifying therapy in ATTR-CM. Primary endpoints were all-cause mortality, 6-minute walk distance (6MWD), Kansas City Cardiomyopathy Questionnaire-Overall Summary (KCCQ-OS) score, and N-terminal pro-B-type natriuretic peptide (NT-proBNP), pooled with a random-effects model. Treatment effects were compared between the monotherapy and baseline stabilizer strata using a mixed-effects model. Results Five trials (ATTR-ACT, APOLLO-B, ATTRibute-CM, HELIOS-B, CARDIO-TTRansform; N=3497) were included. Disease-modifying therapy reduced all-cause mortality (risk ratio, 0.76; 95% confidence interval [CI], 0.66-0.87; I2=0%) and improved 6MWD (pooled standardized mean difference [SMD], 0.43; 95% CI, 0.20-0.67), KCCQ-OS score (SMD, 0.37; 95% CI, 0.19-0.55), and NT-proBNP (SMD, -0.53; 95% CI, -0.89 to -0.18). The mortality benefit was similar whether therapy was given alone or added to a background stabilizer (pooled risk ratio, 0.77 vs. 0.71; P for interaction = 0.59), but treatment effects on 6MWD (pooled SMD, 0.49 vs. 0.14), KCCQ-OS score (0.44 vs. 0.07), and NT-proBNP (-0.65 vs. -0.13) were smaller among patients receiving a background stabilizer (P for interaction = 0.012, <0.001, and 0.029, respectively). Conclusion Disease-modifying treatments reduced all-cause mortality and favored functional capacity, health status, and NT-proBNP outcomes in patients with ATTR-CM. Exploratory subgroup analyses showed smaller treatment effects on 6MWD, KCCQ-OS score, and NT-proBNP among patients receiving a background stabilizer, with no statistically significant difference in the mortality effect according to baseline stabilizer use.
Matching journals
The top 9 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Which patients did recent trials in transthyretin amyloid cardiomyopathy select? -Insights from a prospective patient registry 95%
- Right Ventricular Dysfunction: An Overlooked Predictor of Sudden Cardiac Death and Arrhythmic Events -- A Meta-Analysis 91%
- Clinical presentation, disease course and outcome of COVID-19 in hospitalized patients with and without pre-existing cardiac disease – a cohort study across sixteen countries 90%
Similar papers in this journal
- Allele-specific silencing ameliorates restrictive cardiomyopathy due to a human myosin regulatory light chain mutation 91%
- Comparison of Long-term Outcomes of Early Surgery Versus Conventional Treatment for Asymptomatic Severe Mitral Regurgitation: A Propensity Analysis 90%
- Effects of catheter-based renal denervation in hypertension: a systematic review and meta-analysis 90%
Similar papers in this journal
- Multispecialty multidisciplinary input into comorbidities in heart failure reduces hospitalisation and clinic attendance 90%
- Cardiac Post-acute Sequelae symptoms of SARS-CoV-2 in Community-Dwelling Adults: Cross-sectional Study 89%
- Vascular Comorbidities Worsen Prognosis of Patients with Heart Failure Hospitalized with COVID-19 89%
Similar papers in this journal
- The Role of GLP-1 Receptor Agonists in Managing Cancer Therapy-Related Cardiac Dysfunction 91%
- Hypertrophic Cardiomyopathy -- The Impact of Age at Diagnosis of the Proband on Genetic Yield, Clinical Presentation, Outcomes, and Yield of Family Screening 90%
- Development and validation of imaging-free myocardial fibrosis prediction models, association with outcomes, and sample size estimation for phase 3 trials 90%
Similar papers in this journal
- Lipid-Modulating Agents for Prevention or Treatment of COVID-19 in Randomized Trials 90%
- Prevalence and clinical importance of titin truncating variants in adults without known congestive heart failure 90%
- Comparative Effectiveness of Second-line Antihyperglycemic Agents for Cardiovascular Outcomes: A Large-scale, Multinational, Federated Analysis of the LEGEND-T2DM Study 90%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.